Data Suggest Potential for Immunotherapy in HCC

Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.

Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses interesting data presented for hepatocellular carcinoma (HCC) at the 2018 Gastrointestinal Cancers Symposium.

One analysis looked at the role of neoadjuvant immunotherapy in patients with resectable HCC. While this is a small subset of patients, Wadlow says that 3 of the 8 patients had pathologic complete responses, 2 with a checkpoint combination and 1 with a single-agent PD-L1 inhibitor.